Arocef Tablet, Capsule, Powder For Suspension, Pediatric Drops
Arocef is an orally administered extended spectrum, semi-synthetic 3rd generation antibiotic of cephalosporin class. Like other β-lactam antibiotics it is a bactericidal drug that acts by inhibition of bacterial cell wall synthesis.
Cefpodoxime is used for the treatment of patients infected with susceptible strains of micro-organisms which include a wide range of gram-positive & gram-negative bacteria. As it is highly stable in presence of b-lactamase enzyme, so it is more effective against gram-positive bacteria than other 3rd generation oral Cephalosporins.
The susceptible organisms include gram-positive bacteria eg. S. aureus (including penicillinase producing strains), S. saprophyticus, S. pneumoniae, S. pyogenes, S. agalactiae, P. magnus and gram-negative bacteria eg. E. coli, K. pneumoniae, H. influenzae (including b-lactamase producer & Ampicillin resistant strains), M. catarrhalis, N. gonorrhoeae (including penicillinase producing strains), P. mirabillis, C. diversus, H. parainfluenzae, K. oxytoca, P. vulgaris, P. rettgeri.
Ximeprox is used for the following diseases:-
(1) Lower respiratory tract infection: Acute community-acquired pneumonia, Acute bacterial exacerbation of chronic bronchitis; (2) Upper respiratory tract infection: Acute otitis media, Acute maxillary sinusitis, Pharyngitis, Tonsillitis; (3) Sexually transmitted diseases: Acute uncomplicated urethral & cervical gonorrhea, Acute ano-rectal infection in woman caused by N. gonorrhoeae; (4) Uncomplicated urinary tract infection: Cystitis, Pyuria; (5) Skin & soft tissue infections: Furuncle, Cellulitis, Subcutaneous abscess, infectious atheroma & periproctal abscess (6) Enteric fever.
|Weight||500mg, 125mg/5ml, 100mg/ml|
|Type||Tablet, Capsule, Powder For Suspension, Pediatric Drops|
|Therapeutic Class||Third generation Cephalosporins|
|Manufacturer||Arrowin Pharmaceuticals, Eskayef Bangladesh Ltd|
|Available Country||India, Bangladesh|
|Last Updated:||June 23, 2021 at 9:00 am|
Table Of contents
Ximeprox should be administered orally with food to enhance absorption. Ximeprox suspension may be given without regard to food.
15 days - 6 months : 4 mg/kg every 12 hours
6 months - 2 years : 40 mg every 12 hours
3 - 8 years : 80 mg every 12 hours
over 9 years : 100 mg every 12 hours
Patients with renal dysfunction: For patients with severe renal impairment (creatinine clearance <30 ml/min) the dosing intervals should be increased to 24 hourly.
Patients with liver cirrhosis: Cefpodoxime proxetil pharmacokinetics in cirrhotic patients are similar to those in healthy subjects. Dose adjustment is not necessary in this population.
Direction for Reconstitution of suspension:
For 100 ml suspension : Add 50 ml (10 measuring spoonful) of boiled and cooled water to the dry mixture in the bottle. For ease of preparation add water to the bottle in two portions. Shake well after each addition until all the powder is in suspension.
For 50 ml suspension : Add 25 ml (5 measuring spoonful) of boiled and cooled water to the dry mixture in the bottle. For ease of preparation add water to the bottle in two portions. Shake well after each addition until all the powder is in suspension.
For 50 ml DS suspension : Add 25 ml (5 measuring spoonful) of boiled and cooled water to the dry mixture in the bottle. For ease of preparation add water to the bottle in two portions. Shake well after each addition until all the powder is in suspension.
Note: Shake the suspension well before each use. Keep the bottle tightly closed. The reconstituted suspension should be stored in a cool and dry place, preferably in refrigerator and unused portion should be discarded after 10 days.
Cefpodoxime has very few side effects. The side effects include diarrhea, nausea, skin & vaginal fungal infection, abdominal pain, headache, chest pain, myalgia, dyspepsia, dizziness, vertigo, cough etc. In children incidence of fungal skin rash is more than adults.
In patients with transient or persistent reduction in urinary output due to renal insufficiency, the total daily dose of cefpodoxime proxetil should be reduced. Cefpodoxime, like other cephalosporins, should be administered with caution to patients receiving concurrent treatment with potent diuretics. As with other broad spectrum antibiotics, prolonged use of cefpodoxime proxetil may result in overgrowth of non-susceptible organisms. Repeated evaluation of the patient's condition is essential.
Antacids or H2-blockers may decrease the absorption of cefpodoxime. Reduced renal excretion with probenecid.
Pregnancy & Breastfeeding use
There are no adequate and well-controlled studies on Cefpodoxime proxetil use in pregnant woman, but it was found neither teratogenic nor embryocidal in animal trial. However, the drug should be used during pregnancy only if clearly needed. In nursing mother, Cefpodoxime is excreted in breast milk & there is potential risk of serious reactions in nursing infants, so a decision should be made whether to discontinue breast feeding or to discontinue the drug.
Cefpodoxime is contraindicated in patients with known allergy to the cephalosporin class of antibiotics.
Renal Impairment: Patients with renal dysfunction: For patients with severe renal impairment (creatinine clearance <30 ml/min) the dosing intervals should be increased to 24 hourly.
Hepatic Impairment: The dosage does not require modification in cases of hepatic impairment.
Symptoms: Nausea, vomiting, epigastric distress and diarrhoea.
Management: Haemodialysis or peritoneal dialysis may be useful in the event of a serious toxic reaction particularly if renal function is compromised.
Interaction with other Medicine
Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma level by 24% to 42% and the extent of absorption by 27% to 32% respectively.
Probenecid: Renal excretion of Cefpodoxime proxetil was inhibited by Probenecid and resulted in an approximately 31% increase in AUC.
Nephrotoxic drugs: Close monitoring of renal function is advised when Cefpodoxime proxetil is administered concomitantly with compounds of known Nephrotoxic potential.
Capsule: Store below 30° C, protected from light and moisture.
Powder for suspension: Store below 25° C, protected from light and moisture.
After reconstitution: The suspension can be used within 7 days if be kept at room temperature and within 14 days if be kept in refrigerator (2° to 8° C). Always keep the bottle tightly closed.